AbbVie Inc.
For the period ended Dec 31, 2025. Filed Feb 20, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 20, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. PROPERTIES
AbbVie's corporate offices are located at 1 North Waukegan Road, North Chicago, Illinois 60064-6400. As of December 31, 2025, AbbVie owns or leases approximately 600 facilities worldwide, containing an aggregate of approximately 19.4 million square feet of floor space dedicated to production, distribution and administration. AbbVie's significant manufacturing sites are in the following locations:
| United States | Outside the United States |
|---|---|
| Abbott Park, Illinois* | Campoverde di Aprilia, Italy |
| Barceloneta, Puerto Rico | Clonshaugh, Ireland |
| Branchburg, New Jersey* | Cork, Ireland |
| Cincinnati, Ohio | La Aurora, Costa Rica |
| Dublin, California* | Ludwigshafen, Germany |
| Irvine, California | Pringy, France |
| North Chicago, Illinois | Singapore* |
| Waco, Texas | Sligo, Ireland |
| Worcester, Massachusetts* | Westport, Ireland* |
| Wyandotte, Michigan* | |
- Leased property.
AbbVie believes its sites are suitable and provide adequate production capacity for its current and projected operations. There are no material encumbrances on AbbVie's owned properties.
AbbVie distributes products through a network of central and regional distribution centers, with its central distribution centers located in the U.S. and Europe. AbbVie also has research and development sites in the United States located at: Abbott Park, Illinois; Branchburg, New Jersey; Cambridge, Massachusetts; Irvine, California; Madison, New Jersey; Madison, Wisconsin; North Chicago, Illinois; Pleasanton, California; San Diego, California; South San Francisco, California; Waltham, Massachusetts, and Worcester, Massachusetts. Outside the United States, AbbVie's principal research and development facilities are located in Ludwigshafen, Germany and Oxford, United Kingdom.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.